No Reduced CVD Risk for SBP <120 mm Hg in Type 2 Diabetes

Share this content:
No Reduced CVD Risk for SBP &#60;120 mm Hg in Type 2 Diabetes
No Reduced CVD Risk for SBP <120 mm Hg in Type 2 Diabetes

WEDNESDAY, April 11, 2018 (HealthDay News) -- For patients with type 2 diabetes mellitus (T2DM), there is no reduction in cardiovascular disease (CVD) risk with achieved systolic blood pressure (SBP) of <120 mm Hg versus <130 or <140 mm Hg, according to a study published online March 28 in Diabetes Care.

Eric Yuk Fai Wan, from the University of Hong Kong, and colleagues conducted a retrospective cohort study of 28,014 primary care adult patients with T2DM with no prior CVD diagnosis. The authors identified a total of 2,079, 10,851, and 15,084 matched patients with achieved SBP measurements of <120, <130, and <140 mm Hg, respectively.

The researchers found that the incidence of CVD was 15.3, 9.1, and 10.8 percent in patients who achieved SBP measures of <120, <130, and <140 mm Hg, respectively, over a median follow-up of 4.8 years (incidence rates, 34.3, 20.4, and 21.4 per 1,000 person-years, respectively). Compared with achieved SBP <130 mm Hg and achieved SBP of <140 mm Hg, achieved SBP <120 mm Hg was correlated with an increased risk of CVD (hazard ratios, 1.75 and 1.67, respectively). A significant reduction in CVD risk was seen for patients aged <65 years with achieved SBP <130 versus <140 mm Hg (hazard ratio, 0.81).

"Our findings support a SBP treatment target of 140 mm Hg and suspect no risk reduction attenuation on CVD for lower SBP targets," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Increase Seen in Salmonella Illnesses From Ground Beef

CDC: Increase Seen in <i>Salmonella</i> Illnesses From Ground ...

246 people now sickened; 59 people have been hospitalized; no deaths reported to date

Epinephrine Personal Autoinjectors Cost-Effective at 24

Epinephrine Personal Autoinjectors Cost-Effective at &#36;24

Based on 10-fold fatality risk difference, value-based price for personal epinephrine $24

Burden of Liver Cancer Rising in Medicare Patients

Burden of Liver Cancer Rising in Medicare Patients

Coexistence of other liver conditions tied to even higher risk for death, health care costs

is free, fast, and customized just for you!




Already a member?

Sign In Now »